paper
examin
relationship
biomed
polici
entrepreneuri
r
strategi
public
health
program
unabl
provid
effect
afford
treatment
infecti
diseas
poor
govern
becom
open
privat
sector
contribut
polici
object
rare
find
new
ventur
commerci
healthcar
innov
neglect
diseas
two
case
studi
entrepreneuri
ventur
uk
china
provid
evid
resourceconstrain
firm
mobil
particip
policyspecif
ecosystem
achiev
goal
new
vaccin
develop
tuberculosi
ecosystem
analysi
reveal
innov
busi
model
align
strategi
nation
polici
object
widespread
recognit
import
biomed
innov
recent
translat
r
treatment
diseas
affect
poor
recogn
public
polici
object
call
integr
biomed
innov
public
health
program
new
busi
model
part
enterpris
innov
drug
vaccin
face
challeng
includ
risk
attach
technic
research
develop
r
market
uncertainti
long
invest
horizon
r
fund
life
scienc
ventur
engag
demand
r
effort
fund
scarc
burki
pisano
technolog
push
insuffici
also
necessari
pull
innov
market
provid
afford
product
meet
need
patient
popul
infecti
diseas
burden
weigh
heavili
lower
socioeconom
group
tuberculosi
ageold
diseas
affect
onethird
world
popul
tb
burden
highest
develop
countri
rise
drugresist
tuberculosi
poor
area
develop
countri
also
caus
concern
current
tb
vaccin
use
public
health
campaign
advanc
littl
sinc
first
vaccin
discoveri
earli
centuri
multin
pharmaceut
compani
limit
interest
innov
improv
expect
yield
suffici
return
satisfi
sharehold
trouiller
et
al
view
econom
moral
imper
meet
need
patient
worldwid
privat
sector
r
initi
push
forward
combat
tuberculosi
harper
requir
new
sourc
fund
new
relationship
public
sector
organ
philanthrop
trust
medic
foundat
entrepreneuri
innov
paper
explor
firm
attempt
commerci
improv
tb
vaccin
light
nation
biomed
polici
research
question
center
busi
model
promot
effect
partnership
privat
public
sphere
entrepreneuri
firm
commerci
new
vaccin
associ
question
influenc
exert
polici
prioriti
strategi
busi
model
firm
submit
question
use
address
examin
evid
relationship
form
around
ecosystem
effort
combat
diseas
relev
nation
program
differ
substanti
explor
whether
common
theme
aris
commerci
tb
vaccin
new
ventur
highli
divers
nation
set
inform
analysi
use
evid
two
case
studi
tb
vaccin
innov
one
base
unit
kingdom
one
base
china
benefit
comparison
kind
factor
found
impact
outcom
context
provid
rational
comparison
search
contextdepend
factor
may
explain
differ
case
final
examin
whether
conceptu
approach
propos
like
illumin
similar
differ
studi
technolog
polici
biomed
program
beyond
two
case
studi
case
studi
firm
resourceconstrain
face
challeng
obtain
invest
fund
r
neglect
diseas
predominantli
affect
poor
conduct
crosscas
comparison
busi
model
use
implement
innov
strategi
see
relat
distinct
polici
context
conceptu
issu
term
innov
ecosystem
adner
one
particip
form
relationship
meet
goal
togeth
could
achiev
individu
studi
demonstr
applic
ecosystem
theori
busi
model
approach
firm
strategi
may
illumin
issu
innov
elsewher
aim
leverag
polici
resourc
biomed
technolog
innov
innov
emerg
new
invent
combin
invent
market
capabl
creat
valu
user
afuah
freeman
innov
deriv
technolog
advanc
stem
multipl
sourc
includ
tradit
center
knowledg
product
corpor
pharmaceut
r
laboratori
research
institut
univers
lundval
et
al
howev
encourag
new
sourc
innov
ecosystem
multipl
particip
adner
kapoor
moor
may
requir
coordin
knowledg
flow
make
avail
necessari
resourc
entrepreneuri
firm
key
sourc
innov
sinc
industri
revolut
nairn
despit
myth
solo
entrepreneur
achiev
prodigi
feat
practic
entrepreneur
like
succeed
mobil
support
offer
reciproc
return
help
realiz
opportun
busi
ecosystem
enabl
new
entrepreneuri
firm
work
establish
busi
organ
gain
legitimaci
reduc
risk
eisenhardt
schoonhoven
investig
whether
ecosystem
may
also
link
public
privat
particip
product
relationship
achiev
common
goal
case
firm
form
new
ecosystem
order
creat
opportun
innov
previous
recogn
garnsey
leong
requir
busi
model
make
viabl
innov
manner
case
innov
new
firm
attempt
gain
access
exist
ecosystem
show
contribut
make
particip
includ
govern
organ
govern
mani
polici
lever
encourag
innov
deliber
foster
ecosystem
support
innov
rel
new
notion
howev
natur
extens
polici
encourag
nation
coordin
industri
research
educ
initi
exampl
govern
priorit
area
innov
public
fund
scheme
strateg
infrastructur
invest
inclus
strategi
set
ministeri
level
econom
invest
human
knowledg
capit
need
sustain
polici
environ
creat
long
term
predict
incent
privat
sector
entrepreneur
propens
challeng
convent
think
schumpet
entrepreneur
draw
upon
prior
knowledg
understand
recogn
new
opportun
social
econom
fill
market
knowledg
gap
seelo
mair
shane
often
includ
provid
new
valu
proposit
drucker
obtain
build
organ
resourc
new
way
realiz
opportun
garnsey
penros
entrepreneuri
think
provid
strateg
mean
access
extern
resourc
benefit
new
resourc
combin
burgelman
hitt
et
al
type
innov
achiev
strateg
goal
requir
new
busi
model
embodi
partnership
allianc
sanchez
heen
innov
ecosystem
approach
enrich
concept
open
innov
extend
beyond
ecosystem
busi
particip
includ
govern
institut
polici
input
approach
build
research
partnership
allianc
open
innov
studi
explor
partnership
compens
absenc
vertic
integr
chesbrough
ecosystem
concept
goe
beyond
convent
industri
valu
chain
includ
funder
resourc
provid
standard
setter
complementari
innov
make
possibl
particip
gener
valu
togeth
ecosystem
approach
allow
element
joint
valu
creation
includ
strateg
analysi
adner
kapoor
ecosystem
social
dimens
enabl
creation
share
econom
social
valu
porter
kramer
support
ecosystem
reduc
innov
risk
execut
coinnov
adopt
firm
combat
diseas
poverti
li
garnsey
entrepreneur
excel
coupl
activ
incent
orchestr
interact
other
provid
resourc
lack
must
provid
form
reciproc
one
way
may
join
ongo
ecosystem
make
contribut
other
reciproc
support
innov
evid
show
ecosystem
organ
combat
tb
form
anew
uk
jointventur
new
chines
life
scienc
firm
gain
entri
benefit
exist
health
ecosystem
use
concept
ecosystem
identifi
commun
explor
differ
two
case
studi
busi
model
approach
strategi
firm
unit
analysi
complement
ecosystem
approach
busi
model
render
oper
firm
strateg
object
may
may
made
explicit
teec
view
busi
model
way
firm
organ
creat
secur
valu
accord
strateg
goal
particip
ecosystem
creat
valu
collect
also
enabl
valu
gener
individu
unit
requir
surviv
joint
valu
therebi
creat
may
social
well
econom
thu
propos
innov
firm
busi
model
repres
attempt
respond
secur
impact
potenti
support
ecosystem
strateg
goal
difficult
imposs
ventur
achiev
poor
lack
purchas
power
price
access
limit
effect
demand
despit
undeni
need
new
technolog
slow
reach
poor
especi
case
healthcar
hotez
et
al
prahalad
hammond
howev
govern
increasingli
provid
polici
lever
encourag
biomed
research
develop
recogn
privat
sector
contribut
may
need
innov
publicpriv
partnership
expand
coverag
new
incent
public
support
structur
engag
privat
sector
medic
innov
underway
buse
waxman
hargreav
et
al
support
r
polici
enabl
virtuou
cycl
demand
innov
product
servic
commiss
intellectu
properti
right
watanab
et
al
biomed
polici
provid
privat
sector
investor
predict
context
strateg
invest
financi
support
innov
effort
tuberculosi
curabl
infecti
diseas
yet
still
claim
million
live
year
million
new
case
per
year
et
al
tb
primarili
affect
lower
socioeconom
group
often
popul
inadequ
access
qualiti
healthcar
easili
spread
dens
urban
area
poor
ventil
sanit
activ
tb
left
untreat
singl
person
infect
peopl
year
kumaresan
et
al
tb
concentr
primarili
popul
develop
countri
onethird
infect
live
india
china
drugresist
variant
rise
develop
develop
countri
fig
tuberculosi
caus
bacterium
call
mycobacterium
tuberculosi
enter
respiratori
tract
primarili
affect
lung
also
affect
almost
tissu
organ
bodi
bacteria
contain
diseas
progress
activ
tb
without
adequ
treatment
infect
fatal
damag
patient
lung
lead
caus
death
econom
product
age
group
adult
age
decreas
product
declin
incom
increas
health
expenditur
poor
push
poverti
trap
first
bcg
tuberculosi
vaccin
date
back
bloom
murray
strike
new
tb
vaccin
sinc
new
class
antibiot
diseas
sinc
standard
tb
bcg
vaccin
cost
us
per
dose
administ
billion
peopl
offer
protect
sever
form
childhood
tb
popul
unreli
protect
adult
form
pulmonari
tb
kaufmann
et
al
vaccin
recommend
use
infant
infect
hiv
protect
hiv
infect
adult
new
vaccin
strategi
develop
achiev
higher
level
immun
accomplish
bcg
alon
stop
tb
partnership
work
group
new
vaccin
intern
consortium
work
toward
develop
secondgener
vaccin
effect
popul
subgroup
agegroup
consortium
map
global
tb
vaccin
pipelin
provid
evid
firm
activ
domain
new
tb
vaccin
candid
clinic
trial
tabl
list
sponsor
new
vaccin
research
develop
work
group
tb
vaccin
pipelin
involv
high
profil
institut
show
prioriti
accord
issu
throughout
world
aim
elimin
tuberculosi
global
public
health
concern
emphas
unti
nation
millennium
develop
goal
mdg
combat
infecti
diseas
unit
kingdom
uk
depart
health
follow
framework
global
health
includ
nation
strategi
achiev
mdg
support
health
system
systemat
treat
tuberculosi
depart
health
framework
also
support
uk
depart
intern
develop
dfid
differ
context
peopl
republ
china
tuberculosi
rate
declin
alongsid
increas
econom
develop
china
world
second
highest
absolut
number
tuberculosi
patient
million
new
case
per
year
wang
et
al
china
health
polici
reorient
reactiv
proactiv
prevent
treatment
liu
et
al
biomed
innov
featur
strongli
china
nation
fiveyear
central
plan
china
fiveyear
plan
biotechnolog
rank
number
three
top
prioriti
industri
kpmg
li
woetzel
open
opportun
china
innov
life
scienc
ventur
seek
support
commerci
research
find
uk
china
highlight
tuberculosi
strateg
polici
area
public
health
goal
set
context
intern
develop
assist
uk
wherea
context
china
domest
public
heath
follow
analysi
explor
case
studi
tb
innov
firm
uk
china
respond
strateg
goal
set
govern
studi
entrepreneuri
healthcar
innov
provid
promis
context
studi
ecosystem
translat
research
medic
practic
hodgkinson
pettigrew
sinc
nation
context
differ
common
factor
set
relationship
identifi
impact
would
shown
widespread
interest
would
similar
featur
innov
busi
model
mark
differ
case
provid
insight
impact
nation
system
innov
public
health
research
design
use
two
case
studi
tb
vaccin
innov
exemplar
purpos
test
exist
theori
extend
ecosystem
theori
togeth
busi
model
approach
strategi
order
address
understudi
issu
technolog
polici
public
health
case
may
elucid
translat
process
medic
research
healthcar
practic
case
studi
design
use
effect
exploratori
analysi
analyt
gener
penros
weick
initi
often
desir
choos
particular
organ
precis
special
sens
allow
one
gain
certain
insight
organ
would
abl
provid
siggelkow
p
aim
provid
statist
repres
evid
offer
insight
littl
understood
phenomenon
yin
conceptu
construct
gener
obtain
case
subsequ
explor
multipl
case
studi
largerscal
quantit
analysi
eisenhardt
pool
van
de
ven
two
case
studi
firm
select
data
set
present
tabl
summar
privat
sector
effort
develop
improv
tuberculosi
vaccin
tabl
deriv
stop
tb
partnership
databas
innov
effort
develop
tb
vaccin
triangul
data
set
consult
industri
directori
includ
advocaci
report
treatment
action
group
togeth
report
improv
health
develop
countri
search
process
yield
dataset
privat
sector
firm
joint
ventur
firm
public
enterpris
notforprofit
biotech
enterpris
oxford
emerg
tuberculosi
consortium
oetc
haigui
h
g
biotechnolog
select
exemplar
sever
reason
provid
exampl
innov
firm
highincom
countri
uk
develop
countri
china
respect
h
g
biotech
privat
sector
innov
develop
countri
databas
oetc
jointventur
exampl
compani
approxim
size
two
fulltim
equival
staff
coordin
network
collabor
partner
r
oxfordemerg
tuberculosi
consortium
ltd
oetc
develop
world
clinic
advanc
new
tb
vaccin
candid
unusu
busi
model
interest
jointventur
structur
set
publicli
fund
univers
biopharmaceut
firm
list
new
york
stock
exchang
second
case
studi
shanghai
h
g
biotechnolog
h
g
headquart
scienc
technolog
park
wuxi
china
seek
advanc
one
newest
tb
vaccin
develop
enter
phase
clinic
develop
base
novel
scientif
discoveri
dna
vaccin
use
primari
secondari
data
sourc
studi
primari
sourc
includ
interview
survey
focu
group
expert
delphi
method
semistructur
interview
schedul
devis
understand
firm
busi
model
operation
strategi
creat
relationship
privat
public
sector
organ
interview
data
gather
took
place
octob
april
interview
vari
thirti
minut
two
hour
interview
conduct
respect
compani
founder
gener
manag
team
oetc
r
staff
h
g
archiv
sourc
compani
report
review
materi
extern
funder
govern
polici
white
paper
analyz
complement
check
person
telephon
interview
intern
meet
organ
bring
togeth
facilit
network
subject
wider
research
program
form
part
li
et
al
particip
includ
innov
firm
global
health
ecosystem
participantsfund
involv
public
privat
partnership
technic
expert
world
health
organ
member
stategovern
repres
particip
provid
evid
make
possibl
delphistyl
research
drew
global
expertis
field
tb
vaccin
bryman
key
execut
oetc
h
g
made
detail
present
confer
partner
present
abl
assess
present
case
studi
princip
provid
check
retrospect
bia
facilit
triangul
data
analysi
phase
took
place
three
stage
first
collect
testimoni
semistructur
interview
record
transcrib
textual
analysi
second
step
code
primari
theme
emerg
transcript
case
studi
emerg
theme
crosscompar
analyz
relat
relev
literatur
innov
system
innov
ecosystem
polici
entrepreneurship
allow
us
identifi
set
primari
theme
around
busi
strategi
way
public
health
author
institut
influenc
firm
strategi
final
step
involv
subject
case
studi
evid
independ
analysi
check
accuraci
confer
senior
oetc
h
g
repres
made
present
provid
updat
busi
model
examin
compar
compar
innov
mile
huberman
present
record
publicli
avail
podcast
input
key
opinion
leader
ensur
interpret
evid
took
account
expert
perspect
oetc
offici
form
joint
ventur
public
univers
commerci
transfer
offic
oxford
universityisi
innov
ltd
american
publiclytrad
biopharmaceut
compani
emerg
biosolut
inc
nyse
eb
earli
clinic
work
professor
helen
mcshane
colleagu
univers
oxford
indic
welltoler
vaccin
offer
good
protect
bcg
subject
bcg
vaccin
subject
strong
result
phase
clinic
trial
report
prof
mcshane
recogn
univers
laboratori
oxford
taken
project
far
could
go
academ
set
undertak
next
phase
clinic
trial
phase
iib
studi
demonstr
vaccin
efficaci
requir
signific
financi
resourc
avail
oxford
howev
uk
wellcom
trust
will
provid
onehalf
trial
cost
anoth
donor
could
found
commit
match
fund
thu
start
oetc
conceiv
joint
project
emerg
ecosystem
donor
research
vaccin
produc
isi
innov
univers
technolog
transfer
offic
whollyown
oxford
start
discuss
potenti
develop
partner
behalf
prof
mcshane
research
lab
americanbas
emerg
biosolut
appear
potenti
candid
emerg
biopharmaceut
compani
expertis
develop
manufactur
commerci
vaccin
antibodi
therapi
emerg
also
uk
offic
close
oxford
combin
vaccin
commerci
focu
emerg
uk
presenc
appeal
oxford
chosen
partnership
vehicl
oxford
universityisi
innov
emerg
biosolut
joint
ventur
univers
own
share
emerg
remain
oxfordemerg
tb
consortium
oetc
joint
ventur
announc
juli
oetc
repres
singl
entiti
focus
exclus
tb
vaccin
develop
combin
relev
expertis
asset
univers
oxford
emerg
biosolut
demonstr
commerci
partner
support
program
also
import
factor
secur
fund
wellcom
trust
support
infant
phase
iib
trial
oetc
deal
clinicallyadvanc
outlicens
deal
isi
innov
complet
prof
mcshane
comment
activ
search
develop
partner
bring
onboard
commerci
expertis
acceler
clinic
work
match
funder
wellcom
trust
found
form
aera
global
tb
vaccin
foundat
aera
public
fund
resourc
mobil
oetc
joint
ventur
wellcom
trust
aera
signific
contribut
million
support
phase
iib
clinic
trial
million
total
aera
notforprofit
tb
vaccin
product
develop
partnership
pdp
fund
bill
melinda
gate
foundat
countrydonor
includ
uk
depart
intern
develop
dfid
follow
mobil
fund
resourc
first
phase
iib
clinic
trial
commenc
south
africa
collabor
aera
wellcom
trust
south
african
tuberculosi
vaccin
initi
satvi
univers
cape
town
oetc
resourc
undertak
organ
clinic
trial
thu
partnership
south
african
tuberculosi
vaccin
initi
satvi
provid
necessari
infrastructur
second
phase
iib
studi
evalu
vaccin
hivinfect
adult
commenc
studi
fund
european
develop
countri
clinic
trial
partnership
edctp
via
uk
medic
research
council
mrc
unit
gambia
addit
financi
support
aera
oetc
oetc
oper
busi
model
like
mani
small
startup
biotechnolog
firm
ran
virtual
r
compani
mani
support
stakehold
consortium
two
full
time
staff
joint
ventur
continu
benefit
tb
vaccin
clinic
scientif
expertis
prof
mcshane
oxford
lab
knowledg
find
share
oetc
also
broader
scientif
commun
public
clinic
result
emerg
provid
manufactur
expertis
knowledg
scaleup
suitabl
global
vaccin
suppli
afford
cost
oetc
manag
team
respons
gener
oversight
program
agre
develop
plan
coordin
aspect
oetc
corpor
govern
oetc
joint
ventur
busi
model
structur
three
primari
role
play
bring
market
eventu
patient
remark
dr
jacqui
shea
gener
manag
oetc
first
core
intellectu
properti
hous
within
oetc
legal
counsel
patent
protect
handl
emerg
corpor
capabl
second
oetc
help
coordin
activ
partner
align
develop
object
weekli
monthli
teleconfer
call
held
oetc
partner
well
quarterli
face
face
updat
meet
oetc
act
primari
fund
centr
fund
flow
r
expenditur
moni
flow
one
addit
advantag
joint
ventur
structur
convent
partnership
agreement
commerci
flexibl
exampl
either
one
joint
ventur
partner
could
negoti
buyout
partner
could
continu
take
develop
risk
also
higher
upsid
addit
benefit
addit
neither
develop
partner
wish
continu
share
could
divest
joint
ventur
structur
design
flexibl
capit
potenti
opportun
emerg
hybrid
organ
oetc
abl
har
knowledg
embed
technic
market
capabl
ecosystem
particip
oetc
ensur
knowledg
flow
core
partner
joint
ventur
fig
fig
repres
role
play
oetc
link
partner
coordin
contribut
share
goal
new
vaccin
develop
univers
oxford
uk
public
scienc
fund
direct
research
innov
public
fund
also
came
uk
depart
intern
develop
via
object
fund
research
neglect
diseas
although
oetc
direct
grant
recipi
dfid
tuberculosi
fund
dfid
support
oetc
mani
collabor
dfid
fund
clinic
trial
satvi
also
funder
aera
encourag
global
r
effort
tb
vaccin
fig
show
ecosystem
resourc
mobil
support
oetc
directli
indirectli
collabor
partner
support
share
strateg
object
second
case
studi
haigui
biotechnolog
limit
h
g
present
chines
evid
relationship
entrepreneuri
innov
busi
strategi
biomed
polici
tb
vaccin
commerci
h
g
biotech
found
scientistentrepreneur
dr
li
zhongm
h
g
discoverydriven
biotechnolog
compani
headquart
wuxi
dr
li
receiv
medic
educ
china
went
complet
postdoctor
research
us
food
drug
administr
fda
maryland
dr
li
spent
durat
fdacar
infecti
diseas
depart
found
h
g
base
scientif
principl
illustr
two
natur
paper
lowri
et
al
tascon
et
al
vaccin
use
dna
plasmid
technolog
dr
li
analyz
scientif
proofofconcept
model
contain
paper
rais
question
whether
technolog
could
effect
human
china
carri
world
tb
diseas
burden
sever
acut
respiratori
syndrom
sar
epidem
expos
fragil
public
health
system
polit
strengthen
fight
infecti
diseas
central
govern
increas
fund
public
health
form
million
billion
wang
et
al
feder
provinci
municip
chines
govern
recogn
import
r
follow
polici
attract
best
oversea
return
talent
region
start
new
enterpris
region
incent
includ
startup
busi
tax
break
r
laboratori
facil
reloc
benefit
access
skill
labour
pool
feder
incent
follow
nation
govern
fiveyear
plan
cycl
emphas
govern
focu
fight
hiv
aid
tb
hepat
b
reduc
mortal
morbid
fiveyear
plan
alloc
rmb
yi
billion
usd
grant
scheme
support
research
develop
three
medic
area
fiveyear
plan
rank
biotechnolog
key
prioriti
area
countri
develop
dr
li
first
idea
start
tb
vaccin
biotechnolog
compani
late
knew
us
market
small
us
govern
could
afford
use
secondgener
antibiot
drug
treat
multidrugresist
tb
mdrtb
howev
develop
countri
like
china
suffer
least
mdrtb
case
per
year
govern
resourc
offer
secondlin
treatment
free
public
good
meaning
develop
solut
highdiseas
burden
countri
countri
limit
case
limit
emphasi
said
dr
li
object
also
make
vaccin
afford
averag
patient
china
final
purchas
price
around
rmb
equival
approx
usd
much
cheaper
altern
secondlin
tb
drug
develop
countri
gupta
et
al
still
live
unit
state
dr
li
start
build
resourc
base
new
ventur
first
dr
li
author
chines
book
entitl
new
gener
vaccin
chines
coauthor
collabor
book
gave
credibl
h
g
startup
enterpris
facilit
access
exist
tb
r
ecosystem
within
china
second
dr
li
activ
sought
develop
partner
frequent
visit
china
mani
chapter
coauthor
book
dr
li
learn
import
domest
nation
health
polici
emphasi
reduc
tuberculosi
diseas
burden
within
china
china
polit
leader
premier
wen
jiabao
spoke
frequent
need
work
quickli
fourth
session
nation
peopl
congress
chines
peopl
polit
consult
confer
declar
china
need
build
innovationori
countri
continu
strengthen
basic
research
well
research
technolog
public
welfar
applic
dr
li
made
decis
move
back
china
took
idea
china
privat
seed
fund
match
local
govern
basi
reli
heavili
govern
support
macroeconom
polici
recruit
human
capit
provid
financ
infrastructur
invest
accord
dr
li
regulatori
law
specifi
biolog
therapeut
test
clinic
trial
chines
patient
product
must
produc
china
creat
opportun
chines
firm
dr
li
began
collabor
effort
chines
stateown
biolog
research
institut
manufactur
govern
support
base
fiveyear
review
evalu
product
reach
clinic
test
phase
govern
support
anoth
five
year
give
us
stabil
longterm
plan
state
dr
li
busi
model
develop
h
g
involv
interact
multipl
govern
entiti
constitut
ecosystem
valu
creat
partnership
particip
ecosystem
gain
predict
fund
central
sourc
h
g
mix
privat
investor
govern
grant
fund
launch
r
biotech
busi
resourc
base
center
dr
li
founderentrepreneur
coordin
h
g
develop
partner
h
g
conduct
oper
virtual
network
collabor
one
time
six
peopl
oper
part
h
g
direct
payrol
infrastructur
personnel
access
collabor
agreement
h
g
primari
collabor
stateown
hospit
vaccin
manufactur
site
wuhan
facil
one
six
good
manufactur
practic
gmp
certifi
vaccinemanufactur
locat
china
produc
vaccin
product
h
g
clinic
work
wuhan
facil
stateown
h
g
also
collabor
beij
hospit
futur
clinic
trial
site
phase
work
closer
h
g
wuxi
headquart
dr
li
work
fudan
univers
tb
research
network
centr
use
publicli
fund
laboratori
like
startup
biotechnolog
firm
h
g
oper
tight
cashburn
budget
abl
achiev
research
mileston
base
combin
govern
financi
grant
support
collabor
publicli
fund
infrastructur
laboratori
abl
keep
capit
expenditur
low
oper
share
facil
second
personnel
graduat
student
local
univers
public
institut
will
partner
benefit
appli
experi
gain
staff
industri
govern
recogn
good
result
collabor
project
receiv
increas
govern
grant
fund
busi
model
share
risk
share
reward
scalabl
within
chines
context
focus
public
polici
result
busi
ecosystem
particip
given
incent
share
resourc
input
oper
overal
countri
benefit
increas
nation
innov
capabl
new
entrepreneuri
firm
public
sector
institut
gain
commerci
capabl
vaccin
develop
riski
busi
small
startup
h
g
tri
mitig
individu
firm
risk
diversifi
diagnost
alongsid
primari
vaccin
project
h
g
hous
tb
rapid
diagnost
project
aim
reduc
tb
diagnosi
time
day
import
diagnost
develop
arm
h
g
say
dr
li
diagnost
faster
commerci
timelin
aim
earli
cash
flow
diagnost
sale
sustain
vaccin
project
consist
trend
within
emerg
economi
show
need
biotech
startup
gener
revenu
sourc
surviv
palnitkar
fig
show
polici
direct
ecosystem
h
g
h
g
reli
extern
resourc
provid
collabor
partner
creat
share
valu
busi
model
competit
advantag
h
g
small
startup
vaccin
firm
strong
govern
support
dr
li
gain
expertis
effect
relationship
build
public
resourc
includ
central
govern
municip
govern
fund
domin
h
g
central
govern
provid
major
r
infrastructur
municip
govern
add
second
layer
public
support
incent
bring
oversea
expatri
innov
region
central
fund
uniqu
china
differ
context
face
entrepreneur
work
elsewher
tb
vaccin
use
evid
two
case
studi
explor
connect
innov
firm
attempt
commerci
improv
tuberculosi
vaccin
nation
biomed
polici
research
question
center
way
ecosystem
facilit
benefit
new
busi
model
promot
effect
partnership
privat
public
sphere
new
technolog
commerci
explor
question
seek
evid
relationship
two
new
firm
combat
tb
particip
respect
ecosystem
propos
key
relationship
would
found
link
privat
firm
public
bodi
even
public
health
context
divers
china
uk
section
interpret
evid
case
studi
aim
analyz
interfac
show
wider
relev
experi
inde
find
factor
common
oetc
oxford
h
g
shanghai
despit
contrast
nation
context
firm
work
market
ignor
mainstream
pharmaceut
industri
consign
tuberculosi
famili
neglect
diseas
like
life
scienc
busi
firm
face
challeng
manag
long
term
risk
build
knowledg
creat
learn
environ
pisano
howev
policybas
ecosystem
china
uk
differ
lever
use
combat
tuberculosi
two
firm
construct
distinct
partnership
enhanc
mutual
benefit
context
case
collect
effort
creat
valu
among
group
organ
link
common
goal
share
valu
chain
busi
model
case
studi
firm
design
creat
valu
integr
effort
research
organ
philanthrop
organ
clinic
trial
partnership
consortia
shown
fig
oetc
fig
h
g
particip
ecosystem
stake
achiev
commerci
mileston
align
incent
accordingli
firm
oper
network
partnership
achiev
strateg
r
goal
oetc
join
two
particip
emerg
ecosystem
creat
new
joint
ventur
formal
partnership
h
g
emerg
fill
gap
valu
chain
tb
innov
join
academ
institut
necessari
incub
infrastructur
make
use
product
capabl
stateown
enterpris
neither
oetc
h
g
mani
fulltim
employe
core
employe
play
critic
roleset
maintain
relationship
provid
need
resourc
offer
prospect
move
innov
use
found
critic
firm
identifi
key
ecosystem
partner
align
object
entrepreneuri
ventur
captur
valu
network
collabor
meet
clinic
develop
target
clinic
mileston
achiev
affili
partner
benefit
signal
mileston
offer
invest
posit
impact
associ
public
feed
back
nation
polici
loop
tb
vaccin
develop
member
key
industri
consortium
lobbi
polici
maker
includ
stop
tb
partnership
ventur
influenc
influenc
intern
coordin
bodi
stop
tb
partnership
exert
influenc
macro
health
polici
fund
global
tb
vaccin
portfolio
two
firm
effort
feed
funder
partner
strategi
elimin
tb
global
public
health
burden
scientif
studi
report
clinic
trial
progress
share
annual
meet
stop
tb
partnership
firm
take
part
annual
report
clinic
pipelin
updat
stop
tb
partnership
receiv
report
ecosystem
particip
includ
south
african
tb
vaccin
initi
satvi
european
develop
countri
clinic
trial
partnership
edctp
bill
melinda
gate
foundat
ministri
health
tb
vaccin
aera
product
develop
partnership
report
circuit
individu
ventur
partner
feed
inform
polici
maker
abl
draw
extens
evid
execut
decis
oetc
h
g
share
need
respons
resourc
avail
oetc
built
intern
partnership
usa
seneg
south
africa
coordin
oxford
draw
philanthrop
fund
relationship
foundat
contrast
h
g
biotech
set
multipl
domest
partnership
chines
collabor
allow
share
govern
fund
oetc
joint
ventur
structur
allow
match
resourc
input
philanthrop
wellcom
trust
uk
publicpriv
develop
partnership
bodi
aera
partnership
structur
global
fund
research
oper
clinic
trial
resourc
provid
aera
beneficiari
upstream
foundationphilanthrop
fund
channel
promis
project
portfolio
basi
emerg
biosolut
publicli
list
compani
intern
sharehold
around
world
contribut
support
work
oetc
joint
ventur
h
g
partnership
structur
reflect
polici
prioriti
accord
combat
tb
preval
china
chines
govern
one
domin
resourc
provid
howev
structur
allow
scope
entrepreneuri
opportun
detect
founder
entrepreneur
respond
govern
consult
prioriti
diseas
countri
found
way
match
knowledg
extern
resourc
h
g
enter
exist
ecosystem
mainli
chines
organ
combat
tb
facilit
collabor
rapid
resourc
knowledg
flow
particip
chines
govern
initi
support
center
excel
stimul
new
wave
entrepreneurship
local
lifesci
compani
subsequ
tuberculosi
priorit
plan
public
health
h
g
gain
confid
author
gain
resourc
govern
collabor
partner
h
g
partnership
domest
includ
chines
r
partner
chines
privat
investor
local
central
govern
funder
h
g
intern
connect
howev
facilit
year
spent
us
founder
h
g
sign
memorandum
understand
allow
leverag
aera
intern
technic
capabl
plan
phase
clinic
trial
addit
august
aera
strengthen
intern
polici
tie
china
formal
r
collabor
tb
vaccin
chines
center
diseas
control
prevent
china
cdc
thu
number
common
featur
activ
case
studi
firm
despit
differ
environ
commun
found
compani
proactiv
join
particip
support
ecosystem
task
difficult
oetc
sinc
creat
appropri
ecosystem
one
alreadi
exist
china
case
necessari
founder
identifi
opportun
take
action
realiz
though
natur
opportun
shape
public
polici
case
gain
confid
particip
ecosystem
demonstr
expertis
achiev
r
target
effect
manag
major
differ
case
attribut
larg
part
differ
goal
prioriti
nation
polici
direct
obvious
major
differ
innov
market
economi
privat
financ
major
sourc
invest
uk
plan
market
economi
like
china
chines
govern
provid
support
structur
h
g
though
h
g
earn
support
competit
privat
sector
innov
china
tuberculosi
drugresist
tuberculosi
prioriti
public
health
concern
chines
govern
howev
public
bodi
player
role
individu
innov
recogn
china
start
late
chines
govern
implement
incent
induc
expatri
chines
scientist
entrepreneur
return
china
h
g
founder
dr
li
respond
incent
oetc
oper
market
economi
fund
biotech
ventur
typic
come
privat
sector
form
ventur
capit
howev
avail
vaccin
target
user
develop
countri
econom
return
uncertain
oetc
face
challeng
situat
tb
drug
diagnost
vaccin
need
public
fund
support
accord
dr
adam
stoten
deputi
gener
manag
oetc
oetc
construct
lean
jointventur
leverag
resourc
two
key
contributor
contrast
longer
horizon
chines
govern
privat
sector
player
uk
need
see
result
invest
within
time
span
manag
fund
manag
incent
end
phase
iib
trial
result
show
improv
efficaci
oetc
vaccin
compar
tradit
bcg
altern
target
patient
group
south
african
infant
tameri
et
al
result
joint
ventur
brought
close
univers
oxford
emerg
biosolut
continu
work
separ
oetc
joint
ventur
effort
wast
howev
progress
difficult
field
like
tb
vaccin
alway
go
slow
alway
go
iter
learn
trial
like
state
dr
helen
mcshane
upon
releas
trial
result
first
tb
vaccin
efficaci
trial
infant
year
dr
mcshane
point
inform
gain
trial
feed
global
tb
vaccin
r
pipelin
allow
remain
clinic
vaccin
candid
iter
faster
laboratori
oxford
continu
analyz
result
collect
howev
develop
manufactur
process
arm
joint
ventur
ceas
develop
one
drawback
lean
virtual
organ
busi
model
limit
resourc
secur
work
result
fall
short
expect
ecosystem
creat
safeti
net
build
resili
innov
system
suffici
robust
global
ecosystem
creat
oetc
consider
potenti
also
vulner
weak
link
particular
absenc
long
term
fund
arrang
oetc
fund
project
specif
clinic
mileston
met
busi
model
could
longer
support
market
pressur
vaccin
trial
success
new
resourc
would
flow
joint
ventur
public
privat
sourc
next
clinic
phase
work
combat
tb
view
domest
polici
goal
instead
view
context
uk
aid
intern
develop
context
tb
innov
oetc
might
differ
also
addit
challeng
prove
efficaci
hivposit
populationsad
addit
scientif
standard
vaccin
efficaci
phenomenon
revers
innov
innov
develop
emerg
market
turn
import
applic
advanc
economi
gain
recognit
immelt
et
al
decad
tb
appear
control
tb
case
doubl
london
rais
alarm
public
health
rodger
et
al
prospect
revers
innov
benefit
donor
countri
may
futur
present
order
attract
fund
lobbi
govern
advanc
economi
support
combat
tb
exampl
infecti
diseas
control
strategi
usual
set
govern
public
health
agenc
overlap
defens
strategi
control
threat
nation
secur
use
ecosystem
concept
fast
gain
ground
sometim
critic
use
inappropri
biolog
metaphor
penros
exampl
reject
biolog
analog
believ
determinist
implic
new
ventur
deliber
alter
ecosystem
environ
select
forc
subject
actual
demonstr
proactiv
entrepreneuri
decisionmak
motiv
penros
view
central
object
inquiri
moreov
use
ecosystem
analog
way
organ
relat
idea
liter
analog
energi
transfer
chain
natur
world
anoth
object
may
boundari
ecosystem
ill
defin
critic
level
system
approach
sinc
boundari
system
select
purpos
analysi
evid
firm
transact
busi
model
identifi
ecosystem
boundari
parti
firm
interact
view
particip
ecosystem
busi
model
identifi
player
affect
firm
market
posit
competitor
regul
also
part
firm
ecosystem
may
object
enterpris
requir
publicpriv
partnership
reli
heavili
philanthropi
public
resourc
howev
new
scienc
base
firm
seldom
initi
self
suffici
research
base
enterpris
usual
support
extern
fund
kind
pisano
date
even
innov
firm
focus
diseas
poor
philanthropi
public
grant
fund
key
contributor
earli
stage
research
research
question
focus
innov
busi
model
devis
make
public
polici
relat
question
influenc
polici
exert
firm
strategi
context
polici
prioriti
two
studi
explor
factor
affect
commerci
tb
vaccin
new
ventur
differ
nation
innov
ecosystem
identifi
number
factor
common
enterpris
start
way
address
tb
neglect
diseas
poor
commerci
incent
innov
evid
case
opportun
recognit
typic
entrepreneurship
attempt
made
use
prior
knowledg
build
capabl
neither
case
realist
entrepreneur
go
alon
sought
align
busi
model
public
polici
prioriti
order
access
resourc
enterpris
member
global
consortium
stop
tb
partnership
afford
legitimaci
help
lobbi
govern
govern
beyond
border
howev
differ
two
case
consider
close
link
respect
govern
prioriti
chines
entrepreneur
gain
confid
author
order
admit
ongo
ecosystem
vaccin
innov
china
admit
firm
guarante
fund
support
long
result
achiev
prioriti
accord
control
tb
china
uk
ventur
necessari
build
innov
ecosystem
organ
seek
creat
valu
collect
done
global
basi
sinc
tb
view
domest
polici
prioriti
uk
author
know
would
occur
uk
polici
environ
favour
oetc
counterfactu
point
need
conduct
comparison
kind
system
technolog
innov
tradit
studi
highincom
countri
focu
innov
commerci
market
abernathi
clark
oecd
teec
ecosystem
approach
enabl
us
identifi
challeng
face
innov
ventur
differ
set
relat
nation
system
innov
encompass
valu
creation
commerci
social
term
lundval
et
al
case
studi
evid
show
research
develop
network
need
r
object
support
ecosystem
promot
govern
polici
help
privat
sector
innov
fill
resourc
gap
commerci
return
lower
requir
market
expect
entrepreneuri
compani
introduc
dynam
element
network
ensur
simpli
reli
govern
handout
seek
new
way
creat
valu
privat
well
public
investor
ecosystem
approach
promot
innov
context
market
failur
appli
mani
sector
beyond
healthcar
exampl
environment
ventur
launch
new
technolog
may
also
requir
creation
support
ecosystem
green
ventur
often
requir
govern
trust
fund
acceler
adopt
need
make
initi
ecosystem
creation
viabl
electr
car
provid
exampl
kley
et
al
social
environment
issu
aris
sustain
develop
object
may
need
align
polici
prioriti
hall
et
al
ecosystem
perspect
appli
poverti
allevi
cooper
effort
deliv
improv
educ
patrino
et
al
intersect
educ
intern
develop
multilater
fund
organ
world
bank
also
devis
polici
influenc
privat
sector
strategyinclud
mani
innov
use
technolog
need
scale
activ
use
costeffect
method
ecosystem
strategi
link
public
polici
privat
sector
entrepreneuri
often
result
new
costeffect
busi
model
creat
deliv
share
valu
paper
strateg
prioriti
guid
polici
shape
environ
within
innov
ventur
oper
set
china
feder
leader
explain
aim
follow
need
follow
polici
make
independ
innov
leapfrog
advanc
key
area
scienc
technolog
support
guid
futur
develop
statement
prioriti
chines
feder
leader
basi
creation
ecosystem
tb
innov
china
relev
guid
principl
uk
health
global
framework
depart
health
promot
health
equiti
within
countri
foreign
domest
polici
particularli
action
social
determin
health
govern
guid
innov
polici
direct
like
achiev
goal
emb
strateg
object
innov
ecosystem
support
emerg
suppli
valu
chain
help
pull
innov
use
particular
case
studi
occur
greater
extent
china
prioriti
polici
case
studi
firm
h
g
better
align
oetc
breakthrough
innov
user
limit
purchas
power
requir
new
relationship
technolog
innov
govern
polici
maker
philanthrop
foundat
also
play
catalyt
role
chines
case
show
govern
polici
mitig
risk
provid
infrastructur
fund
stabil
safeti
net
continu
effort
difficult
technic
area
uk
case
show
potenti
intern
collabor
creation
global
ecosystem
promot
innov
demograph
group
unmet
need
new
busi
model
requir
build
partnership
privat
public
sector
organ
support
ecosystem
work
busi
ecosystem
bridg
public
privat
sector
activ
need
provid
conceptu
framework
tool
advanc
work
biomed
commerci
neglect
diseas
public
health
program
unabl
provid
suffici
access
afford
treatment
infecti
diseas
mainli
affect
poor
govern
acknowledg
need
partnership
work
enlist
help
privat
sector
pull
promis
innov
public
polici
embed
innov
ecosystem
encourag
firm
devis
busi
model
meet
strateg
goal
align
polici
market
incent
weak
need
press
